The management of acute myocardial infarction in patients with diabetes mellitus

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 5, 2003, Pages 319-324

  Williams, Ian L ^a   Noronha, Brian ^a   Zaman, Azfar G ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Acute management; Diabetes mellitus; Myocardial infarction

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLUCOSE; HEPARIN; HIRUDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL ANTIDIABETIC AGENT; POTASSIUM; RAMIPRIL; STREPTOKINASE; SULFONYLUREA DERIVATIVE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BLOOD CLOTTING DISORDER; CORONARY ARTERY DILATATION; CORONARY STENT; DIABETES MELLITUS; DISEASE ASSOCIATION; EXPERIENCE; FOLLOW UP; GLUCOSE METABOLISM; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PATIENT CARE; PROGNOSIS; RESTENOSIS; REVIEW; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 0242382781     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030050201     Document Type: Review

References (49)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-8.
2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. BMJ (Clin Res Ed) 1983;287:867-70.
3. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med 2000;342:1040-2.
4. Lee KL, Woodlief LH, Topol EJ et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91:1659-68.
5. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988;260:3456-60.
6. Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69-75.
7. Granger CB, Califf RM, Young S etal. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol 1993;21:920-5.
8. Mak KH, Moliterno DJ, Granger CB et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997;30:171-9.
9. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999,281:1291-7.
10. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4.
11. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-25.
12. Cleveland JC, Jr., Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997;96:29-32.
13. Woodfield SL, Lundergan CF, Reiner JS et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Cog Cardiol 1996; 28:1661-9.
14. Mahgoub MA, Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell Biochem 1998;180:59-64.
15. Mak KH, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000;35:563-8.
16. Cabin H. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
17. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-22.
18. Kondo T, Kubota I, Tachibana H, Yamaki M, Tomoike H. Glibenclamide attenuates peaked T wave in early phase of myocardial schemia. Cardiovasc Res 1996;31:683-7.
19. Pfeffer MA, Moye LA, Braunwald E et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA 1991;266:528-32.
20. Barron HV, Bowlby LJ, Breen T et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation 1998;97:1150-6.
21. Barbash GI, White HD, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol 1993;22:707-13.
22. Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000;36:355-65.
23. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
24. Cohen M, Demers C, Gurfinkel EP et al. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. Am J Cardiol 1998;82:19L-24L.
25. Morrow DA, Antman EM, Tanasijevic M et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000;36:1812-17.
26. McGuire DK, Emanuelsson H, Granger CB et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J 2000;21:1750-8.
27. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97.
28. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
29. Roffi M, Chew DF, Mukherjee D et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-71.
30. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-8.
31. Malmberg K, McGuire DK. Diabetes and acute myocardial infarction: the role of insulin therapy. Am Heart J 1999;138:S381-S386.
32. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.
33. Diaz R, Paolasso EA, Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998;98:2227-34.
34. Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
35. Younis N, Burnham P, Patwala A, Weston PJ, Vora JR. Beta blocker prescribing differences in patients with and without diabetes following a first myocardial infarction. Diabet Med 2001;18:159-61.
36. Opie LH, Thomas M. Propranolol and experimental myocardial infarction: substrate effects. Postgrad Med J 1976;52(suppl 4): 124-32.
37. Kjekshus J. Heart rate reduction - a mechanism of benefit? Eur Heart J 1987;8(suppl L):115-22.
38. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-32.
39. Thomas K, Ottervanger JF, de Boer MJ, Suryapranata H, Hoorntje JC, Zijlstra F. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. Diabetes Care 1999;22:647-9.
40. Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-73.
41. Van Belle E, Abolmaali K, Bauters C, McFadden EP, Lablanche JM, Bertrand ME. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999;34:476-85.
42. Silva JA, Ramee SR, White CJ et al. Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome. Am Heart J 1999;138:446-55.
43. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000;356:9-16.
44. Boden WE, O'Rourke RA, Crawford MH et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VAN-QWISH) Trial Investigators. N Engl J Med 1998;338:1785-92.
45. Solomon DH, Stone PH, Glynn RJ et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol 2001;38:969-76.
46. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
47. Chan AW, Moliterno DJ. Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET. Curr Opin Cardiol 2001;16:375-83.
48. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
49. Montalescot G, Barragan P, Wittenberg O et al. Abciximab reduces clinical restenosis in diabetic patients undergoing primary stenting for acute myocardial infarction (The ADMIRAL study). Circulation 2001;104:386.